Arvinas, Inc. (ARVN)
8.19
-0.21
(-2.50%)
USD |
NASDAQ |
Sep 15, 10:29
Arvinas Enterprise Value : -11.18M for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | -11.18M |
| September 11, 2026 | -7.915M |
| September 10, 2026 | 9.063M |
| September 09, 2026 | 12.33M |
| September 08, 2026 | 33.22M |
| September 04, 2026 | 53.47M |
| September 03, 2026 | 48.24M |
| September 02, 2026 | 66.53M |
| September 01, 2026 | 46.28M |
| August 31, 2026 | 41.06M |
| August 28, 2026 | 39.75M |
| August 27, 2026 | 43.67M |
| August 26, 2026 | 48.90M |
| August 25, 2026 | 67.18M |
| August 24, 2026 | 50.20M |
| August 21, 2026 | 51.83M |
| August 20, 2026 | 29.63M |
| August 19, 2026 | 72.40M |
| August 18, 2026 | 44.98M |
| August 17, 2026 | 41.06M |
| August 14, 2026 | 26.04M |
| August 13, 2026 | 28.65M |
| August 12, 2026 | 19.51M |
| August 11, 2026 | 27.35M |
| August 10, 2026 | 27.35M |
| Date | Value |
|---|---|
| August 07, 2026 | 11.68M |
| August 06, 2026 | 7.104M |
| August 05, 2026 | -11.18M |
| August 04, 2026 | 28.00M |
| August 03, 2026 | -33.38M |
| July 31, 2026 | -35.34M |
| July 30, 2026 | -17.71M |
| July 29, 2026 | -22.93M |
| July 28, 2026 | -24.24M |
| July 27, 2026 | -22.93M |
| July 24, 2026 | -35.34M |
| July 23, 2026 | -29.46M |
| July 22, 2026 | -20.32M |
| July 21, 2026 | -20.32M |
| July 20, 2026 | -35.99M |
| July 17, 2026 | -36.65M |
| July 16, 2026 | -35.34M |
| July 15, 2026 | -19.02M |
| July 14, 2026 | -19.67M |
| July 13, 2026 | -30.77M |
| July 10, 2026 | -19.67M |
| July 09, 2026 | -2.038M |
| July 08, 2026 | -0.732M |
| July 07, 2026 | 1.227M |
| July 06, 2026 | -7.915M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.23M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | -24.44M |
| Definium Therapeutics, Inc. | 4.361B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 169.40M |
| Revenue (Quarterly) | 249.70M |
| Total Expenses (Quarterly) | 80.30M |
| EPS Diluted (Quarterly) | 2.578 |
| Gross Profit Margin (Quarterly) | 95.92% |
| Profit Margin (Quarterly) | 67.84% |
| Earnings Yield | 1.96% |
| Normalized Earnings Yield | 2.672 |